RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $437
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has maintained a Sector Perform rating on Vertex Pharmaceuticals and raised its price target from $425 to $437.

October 09, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has maintained its Sector Perform rating on Vertex Pharmaceuticals and increased the price target from $425 to $437, indicating a positive outlook.
The increase in the price target from $425 to $437 by RBC Capital suggests a positive outlook for Vertex Pharmaceuticals, which could lead to a short-term increase in stock price. The maintained Sector Perform rating indicates steady performance expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100